5 completed, 3 terminated. 3 Phase 1, 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 3 | 2 | Terminated 2 |
Follow GLPG1690: new trials by email Literature Review of GLPG1690 trials Research Report on GLPG1690
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis GLPG1690 - Systemic Sclerosis | Phase 2 | Terminated | Lakefront Biotherapeutics NV | 31 | 2019-07-18 | 2022-03-29 |
| A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis GLPG1690, Placebo - Systemic Sclerosis | Phase 2 | Completed | Lakefront Biotherapeutics NV | 33 | 2019-01-14 | 2021-05-04 |
| A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care GLPG1690, Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Terminated | Lakefront Biotherapeutics NV | 525 | 2018-11-28 | 2022-07-29 |
| A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care GLPG1690, Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Terminated | Lakefront Biotherapeutics NV | 781 | 2018-11-05 | 2022-07-29 |
| A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Doses of Itraconazole and Voriconazole Are Given to Healthy Volunteers GLPG1690, Itraconazole, Voriconazole - Healthy | Phase 1 | Completed | Lakefront Biotherapeutics NV | 18 | 2018-03-16 | 2018-06-11 |
| Study to Assess Bioavailability of GLPG1690 Given as Oral Capsule or Tablet GLPG1690 - Healthy | Phase 1 | Completed | Lakefront Biotherapeutics NV | 12 | 2017-04-18 | 2017-06-20 |
| Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) GLPG1690 600 mg QD, Placebo QD - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Lakefront Biotherapeutics NV | 23 | 2016-03-01 | 2020-11-06 |
| First-in-Human Single and Multiple Dose of GLPG1690 GLPG1690 single ascending doses, Placebo single ascending doses, GLPG1690, multiple ascending doses, oral suspension - Healthy | Phase 1 | Completed | Lakefront Biotherapeutics NV | 40 | 2014-06-01 | 2015-09-22 |
Idiopathic Pulmonary Fibrosis (3) · Scleroderma, Systemic (2)
Lakefront Biotherapeutics NV (8)
Belgium (5) · United Kingdom (5) · United States (4) · Germany (3) · Italy (3) · Spain (3) · Japan (2) · Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · Chile (1) · Czechia (1) · Denmark (1) · France (1)
Ann Fieuw, MD (1) · Ann Fieuw, MD MSc (1) · Christopher Brearley, BM, MRCP, MFPM (1)
PMID 31012984, PMID 31179008, PMID 37159034, PMID 38288082, PMID 29792287, PMID 34662125
2018 (3), 2014 (1), 2015 (1), 2017 (1), 2019 (1)